We believe that harnessing microgravity has
the potential to lead biotechnology into a
new era of discovery and progress.
Over 2000 experiments on the ISS have proven the beneficial effects of
microgravity on biological systems. Sounds like science fiction to you?
Convince yourself and learn more about benefits for life sciences in microgravity.
Contrary to our planet, where cells are restricted in their
development, they can form complex 3D structures in
microgravity. This offers an entirely new perspective and
enables unexpected new discoveries when conducting
research on the behavior of cells, regenerative medicine
and the testing of drugs.
Ongoing exposure to microgravity initiates immune
dysfunction, bone loss, cardiovascular deconditioning and
loss of skeletal muscle. These artificial representations of
aging and existing diseases on Earth can be useful in
modeling human diseases. Therefore, microgravity enables
valuable insights and testing opportunities for therapeutics
in accelerated models of aging or disease.
The structures of proteins and other large molecules define
their function. Crystallization is a crucial method for
studying the structures of biomolecules. Microgravity allows
molecules to create larger crystals of higher quality, which
gives scientists the opportunity to examine the functions of
molecules important for health and disease in an
unprecedented manner. Pharmaceutical companies can
therefore improve drug design for innovation in drug
manufacturing, storage, specificity and efficacy.
In synthetic biology, the structures and mechanisms of life
are being recreated through back-engineering. This offers
the possibility of a deeper understanding and a better
leveraging of those structures and mechanisms. Space’s
extreme environment adds up to the tools used in synthetic
biology, bringing many benefits to the discipline.
Plants have the ability to “feel” gravity to know in which
direction to grow. In space, this reference point is not
presence, which has considerable effects on plant growth
and development. Studying these phenomena leads to
valuable insights into plant biology, useful for innovating the
ways humans use plants both on Earth and in space.
Microgravity strongly influences fluid dynamics and helps us
to better understand the complexity of biomedical devices
involving fluids. This is especially beneficial at nanoscale
level, where forces like diffusion are substantial.
Microgravity thus helps e.g. to improve drug delivery
systems or healthcare diagnostic tools.
Chief Scientific Officer
Daniela has degrees in Biotech Engineering, Genomics, and Bioinformatics at Cornell, Max Planck , EMBL/CRG with publications in Cell, Science, Nature. Besides co-authoring more than 17 space biology-related papers she is co-chair of NASA GeneLabs Microbiome , ISSOP and ESA Space Omics. She was among the top 4% ESA astronaut candidates, co-founded Poppy Health, was CSO at Bumrungrad hospital and is now leading yuri’s transition to a biotech company.
Scientific Advisory Board
Christopher Mason is a professor of Genomics, Physiology and Biophysics at Weill Cornell Medicine New York. Chris has published over 275 publications in journals like Cell, Science, Nature and has been cited almost 30,000 times. He and his team completed the first-ever sequencing of DNA on the ISS. Among other awards, he won the “Brilliant Ten” scientist of Popular Science. And if you want to know what he is really up to, check out his great book “The Next 500 years”.
Jessica studied chemistry at the Free University of Berlin and completed her PhD in biochemistry in a research group at the Charité Berlin on “Proteome analysis of human thyroid cells cultured under simulated microgravity”. She participated in several scientific space experiments (SIMBOX on ShenZhou-8, Cellbox-1 and SPHEROIDS on ISS).
Pharma Advisor & Investor
Stefan Oschmann started his career in pharma occupying diverse managing positions at MSD. He then worked at Merck, starting by leading the Healthcare department and developing the global strategy to become CEO of Merck in 2016. With his award-winning leadership skills he served Merck until 2021. Currently, Stefan works as chairman at both UCB and AiCuris Anti-infective Cures.
Scientific Advisory Board
Afshin has a PhD from Florida State in physics and made a transition to cancer, systems biology, space biology, and radiation biology. As Assistant Professor at Tufts University he worked in the areas of cancer incl. microRNAs, aging and novel immunotherapies. He holds positions at NASA Ames, Nasa Genelabs and Broad Institute of MIT and Harvard where he works on microRNAs and mitochondria in space, COVID-19 and the impact of high altitude on human biology.
Scientific Advisory Board
Richard holds a PhD from the University of Nottingham and has over 10 years of experience as a NASA funded space biology researcher with 6 ISS experiments under his belt. As part of being co-chair of the NASA Genelabs Plant Analysis he provides access to space biology data. He was a selected representative of the American Academy of Science at the Future Leaders in Space Science and won the Thora Halstead award.